Convalescent Plasma for Severely Ill Hospitalized Participants with COVID-19 Pneumonia Caused by SARS-CoV-2

Convalescent Plasma for Severely Ill  Hospitalized Participants with COVID-19 Pneumonia Caused by SARS-CoV-2

Brief description of study

This open-label, controlled, phase 1 trial will assess the safety and efficacy of convalescent plasma in severely ill, hospitalized participants with pneumonia due to COVID-19. This study will enroll adults 18 years old and older, including pregnant women. A total of 80 eligible participants will be randomized to receive either 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 and standard of care (treatment arm) or standard of care alone (control arm). 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    COVID
  • Age: - 99 Years
  • Gender: All


Updated on 10 Mar 2021. Study ID: 843003

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center